echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > AstraZeneca's new crown antibody cocktail therapy can provide protection for at least 6 months in high-risk groups

    AstraZeneca's new crown antibody cocktail therapy can provide protection for at least 6 months in high-risk groups

    • Last Update: 2022-05-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    AstraZeneca said today that its long-acting antibody cocktail, Evusheld (tixagevimab and cilgavimab), compared with placebo in a late-stage pre-exposure prophylaxis trial, reduced patients with symptomatic COVID-19 infection six months later.
    83% lower risk
    .
    The results are in line with data from the main analysis published last summer
    .
    At the time, AstraZeneca said the treatment was able to reduce the risk of symptomatic infection by 77% compared to a placebo
    .
    There were also no serious illnesses or COVID-19-related deaths among patients treated with Evusheld over a six-month period
    .
    In contrast, there were five serious cases and two related deaths in the placebo group, AstraZeneca said
    .
    In the Phase 3 Provent trial, more than 75% of participants were enrolled because their COVID-19 infection was likely to progress to moderate to severe disease
    .
    The study population included immunocompromised individuals with insufficient responses to existing vaccines
    .
    AstraZeneca said the therapy was well tolerated and there were no safety concerns during the initial analysis or the six-month analysis period
    .
    The trial data, published Wednesday in the New England Journal of Medicine, further confirm the use of Evusheld to help prevent both symptomatic and severe COVID-19, Mene Pangalos, executive vice president of biopharmaceutical research and development at AstraZeneca, said in a press release.
    Clinical evidence, especially for those who fail to develop an adequate antibody response to the vaccine and need additional protection
    .
    In December, Evusheld received emergency approval from the U.
    S.
    FDA for the prevention of COVID-19 infection before exposure to the virus
    .
    Specifically, the U.
    S.
    FDA authorized Evusheld for use in people with moderately to severely compromised immune systems
    .
    In addition, people with adverse reactions to the COVID-19 vaccine can also receive Evusheld treatment
    .
    Previously, the long-acting antibody combination Evusheld has been approved for marketing in the European Union for pre-exposure prophylaxis of the new coronavirus in a wide range of adults and adolescents (12 years and older and weighing 40 kg and above), and has been approved by the UK Medicines and Healthcare Products Administration ( MHRA) was granted a conditional marketing authorization for pre-exposure prophylaxis against COVID-19
    .
    AstraZeneca had forecast sales of its COVID vaccine would decline in 2022, but some of that loss would be offset by Evusheld
    .
    As of February, the company had received initial orders for 700,000 doses nationwide, and has since added 1 million more doses to the U.
    S.
    market
    .
    Currently, AstraZeneca is applying for emergency use authorization or marketing approval for Evusheld for the prevention and treatment of new crowns worldwide
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.